Cargando…

Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation

We recently proved that exosomes engineered in vitro to deliver high amounts of HPV E7 upon fusion with the Nef(mut) exosome-anchoring protein elicit an efficient anti-E7 cytotoxic T lymphocyte immune response. However, in view of a potential clinic application of this finding, our exosome-based imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Bonito, Paola, Chiozzini, Chiara, Arenaccio, Claudia, Anticoli, Simona, Manfredi, Francesco, Olivetta, Eleonora, Ferrantelli, Flavia, Falcone, Emiliana, Ruggieri, Anna, Federico, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491702/
https://www.ncbi.nlm.nih.gov/pubmed/28694699
http://dx.doi.org/10.2147/IJN.S131309
_version_ 1783247183791783936
author Di Bonito, Paola
Chiozzini, Chiara
Arenaccio, Claudia
Anticoli, Simona
Manfredi, Francesco
Olivetta, Eleonora
Ferrantelli, Flavia
Falcone, Emiliana
Ruggieri, Anna
Federico, Maurizio
author_facet Di Bonito, Paola
Chiozzini, Chiara
Arenaccio, Claudia
Anticoli, Simona
Manfredi, Francesco
Olivetta, Eleonora
Ferrantelli, Flavia
Falcone, Emiliana
Ruggieri, Anna
Federico, Maurizio
author_sort Di Bonito, Paola
collection PubMed
description We recently proved that exosomes engineered in vitro to deliver high amounts of HPV E7 upon fusion with the Nef(mut) exosome-anchoring protein elicit an efficient anti-E7 cytotoxic T lymphocyte immune response. However, in view of a potential clinic application of this finding, our exosome-based immunization strategy was faced with possible technical difficulties including industrial manufacturing, cost of production, and storage. To overcome these hurdles, we designed an as yet unproven exosome-based immunization strategy relying on delivery by intramuscular inoculation of a DNA vector expressing Nef(mut) fused with HPV E7. In this way, we predicted that the expression of the Nef(mut)/E7 vector in muscle cells would result in a continuous source of endogenous (ie, produced by the inoculated host) engineered exosomes able to induce an E7-specific immune response. To assess this hypothesis, we first demonstrated that the injection of a Nef(mut)/green fluorescent protein-expressing vector led to the release of fluorescent exosomes, as detected in plasma of inoculated mice. Then, we observed that mice inoculated intramuscularly with a vector expressing Nef(mut)/E7 developed a CD8(+) T-cell immune response against both Nef and E7. Conversely, no CD8(+) T-cell responses were detected upon injection of vectors expressing either the wild-type Nef isoform of E7 alone, most likely a consequence of their inefficient exosome incorporation. The production of immunogenic exosomes in the DNA-injected mice was formally demonstrated by the E7-specific CD8(+) T-cell immune response we detected in mice inoculated with exosomes isolated from plasma of mice inoculated with the Nef(mut)/E7 vector. Finally, we provide evidence that the injection of Nef(mut)/E7 DNA led to the generation of effective antigen-specific cytotoxic T lymphocytes whose activity was likely part of the potent, therapeutic antitumor effect we observed in mice implanted with TC-1 tumor cells. In summary, we established a novel method to generate immunogenic exosomes in vivo by the intramuscular inoculation of DNA vectors expressing the exosome-anchoring protein Nef(mut) and its derivatives.
format Online
Article
Text
id pubmed-5491702
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54917022017-07-10 Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation Di Bonito, Paola Chiozzini, Chiara Arenaccio, Claudia Anticoli, Simona Manfredi, Francesco Olivetta, Eleonora Ferrantelli, Flavia Falcone, Emiliana Ruggieri, Anna Federico, Maurizio Int J Nanomedicine Original Research We recently proved that exosomes engineered in vitro to deliver high amounts of HPV E7 upon fusion with the Nef(mut) exosome-anchoring protein elicit an efficient anti-E7 cytotoxic T lymphocyte immune response. However, in view of a potential clinic application of this finding, our exosome-based immunization strategy was faced with possible technical difficulties including industrial manufacturing, cost of production, and storage. To overcome these hurdles, we designed an as yet unproven exosome-based immunization strategy relying on delivery by intramuscular inoculation of a DNA vector expressing Nef(mut) fused with HPV E7. In this way, we predicted that the expression of the Nef(mut)/E7 vector in muscle cells would result in a continuous source of endogenous (ie, produced by the inoculated host) engineered exosomes able to induce an E7-specific immune response. To assess this hypothesis, we first demonstrated that the injection of a Nef(mut)/green fluorescent protein-expressing vector led to the release of fluorescent exosomes, as detected in plasma of inoculated mice. Then, we observed that mice inoculated intramuscularly with a vector expressing Nef(mut)/E7 developed a CD8(+) T-cell immune response against both Nef and E7. Conversely, no CD8(+) T-cell responses were detected upon injection of vectors expressing either the wild-type Nef isoform of E7 alone, most likely a consequence of their inefficient exosome incorporation. The production of immunogenic exosomes in the DNA-injected mice was formally demonstrated by the E7-specific CD8(+) T-cell immune response we detected in mice inoculated with exosomes isolated from plasma of mice inoculated with the Nef(mut)/E7 vector. Finally, we provide evidence that the injection of Nef(mut)/E7 DNA led to the generation of effective antigen-specific cytotoxic T lymphocytes whose activity was likely part of the potent, therapeutic antitumor effect we observed in mice implanted with TC-1 tumor cells. In summary, we established a novel method to generate immunogenic exosomes in vivo by the intramuscular inoculation of DNA vectors expressing the exosome-anchoring protein Nef(mut) and its derivatives. Dove Medical Press 2017-06-23 /pmc/articles/PMC5491702/ /pubmed/28694699 http://dx.doi.org/10.2147/IJN.S131309 Text en © 2017 Di Bonito et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Di Bonito, Paola
Chiozzini, Chiara
Arenaccio, Claudia
Anticoli, Simona
Manfredi, Francesco
Olivetta, Eleonora
Ferrantelli, Flavia
Falcone, Emiliana
Ruggieri, Anna
Federico, Maurizio
Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation
title Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation
title_full Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation
title_fullStr Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation
title_full_unstemmed Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation
title_short Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation
title_sort antitumor hpv e7-specific ctl activity elicited by in vivo engineered exosomes produced through dna inoculation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491702/
https://www.ncbi.nlm.nih.gov/pubmed/28694699
http://dx.doi.org/10.2147/IJN.S131309
work_keys_str_mv AT dibonitopaola antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation
AT chiozzinichiara antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation
AT arenaccioclaudia antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation
AT anticolisimona antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation
AT manfredifrancesco antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation
AT olivettaeleonora antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation
AT ferrantelliflavia antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation
AT falconeemiliana antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation
AT ruggierianna antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation
AT federicomaurizio antitumorhpve7specificctlactivityelicitedbyinvivoengineeredexosomesproducedthroughdnainoculation